Journal · Updated 2026-08-11
Found Review 2026: $169 Prepaid or $289 Monthly, and the Prescriber-Chooses Caveat
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Found's cash structure is symmetrical and stark: one hundred sixty-nine dollars a month for either compounded semaglutide or tirzepatide on a twelve-month plan paid up-front, against two hundred eighty-nine month-to-month — a seventy-one percent spread that is the second-widest in our teaser index — plus an insurance track (ninety-nine prepaid annual, or one ninety-nine monthly plus copay) that makes Found one of the few compounded-era programs with a real coverage pathway. Verified July 25, 2026 on Found's own pricing page per our source records; reported status. The caveat that reframes everything: Found's model is personalized prescribing across drug classes, and the clinician may recommend a non-GLP-1 medication — which for a buyer specifically shopping the tirzepatide floor is a feature-shaped risk worth pinning before any prepayment.
The structure: symmetric prices, asymmetric shapes
Two things distinguish the ladder. First, molecule-identical pricing — tirzepatide at semaglutide's rate is unusual (tirzepatide costs more nearly everywhere), which makes Found's one sixty-nine prepaid genuinely notable on the tirzepatide side: it undercuts bmiMD's one thirty-nine? No — it doesn't; one sixty-nine prepaid-upfront sits above the one twenty-five-to-one thirty-nine committed tier and its real comparison is the shape: a prepaid year (Trimi-style concentration, roughly two thousand dollars upfront) against monthly-billed commitments at lower rates, which the arithmetic loses. Second, the monthly rate: two eighty-nine is the flexibility tier's ceiling, a hundred-plus over the one sixty-nine-to-one seventy-nine no-commitment leaders — the spread exists to sell the prepay. The insurance track is the quiet asset: for a covered buyer, ninety-nine prepaid or one ninety-nine-plus-copay routes toward the coverage math few compounded programs even attempt.
The caveat, the questions, and the verdict
Personalized prescribing means the intake's output is the clinician's call — a defensible clinical model, and a real mismatch risk for the buyer who arrived for a specific molecule at a specific price. So the pre-payment questions: if the recommendation isn't the GLP-1 I came for, what are my options and refund terms on the prepaid plan? What exactly is my medication and dose before the annual charge, in writing? Plus the standards: pharmacy name, exit mechanics, credit-card rail on any prepayment. Verdict by buyer: the insurance-eligible land well here; the cash tirzepatide-floor shopper finds better rates in safer shapes (bmiMD's one thirty-nine monthly-billed, NexLife's one thirty-nine promo); and the flexibility buyer should read two eighty-nine as the price of not deciding — then decide, because this market charges handsomely for indecision and Found's ladder is the clearest printout of the bill.
Questions people ask
How much does Found cost for GLP-1s?
Cash: $169/month for either compounded semaglutide or tirzepatide on a twelve-month plan paid up-front, or $289 month-to-month (verified on Found's pricing page, July 2026). Insurance track: $99/month prepaid annual or $199/month plus copay. The 71% prepay-vs-monthly spread is the second-widest we've measured.
Does Found guarantee I'll get tirzepatide?
No — Found's model is personalized prescribing across drug classes, and the clinician may recommend a different medication. Before any prepayment, get in writing: your specific medication and dose, and the refund terms if the recommendation isn't the GLP-1 you enrolled for.
Is Found's $169 prepaid plan a good deal?
It's molecule-identical pricing (rare) but a prepaid-upfront shape (~$2,000 committed on day one) that the monthly-billed committed tier beats on rate: bmiMD's $139 tirzepatide and $99 semaglutide twelve-month tiers bill monthly. Found's real edge is its insurance track; its cash monthly ($289) is the flexibility ceiling, not a contender.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.